Literature DB >> 8647374

New MspI polymorphism at +83 bp of the human apolipoprotein AI gene: association with increased circulating high density lipoprotein cholesterol levels.

X L Wang1, R Badenhop, K E Humphrey, D E Wilcken.   

Abstract

We recently showed that loss of a MspI restriction site in the 5'-end (intron 1) of the apolipoprotein (apo) AI gene is due to a C to T transition (+83 bp) and/or a G to A transition (+84 bp). Since this region may be relevant to the regulation of apo AI gene expression and therefore to plasma high density lipoprotein cholesterol (HDL-C), we explored the association between this MspI polymorphic site and circulating HDL-C levels in 243 healthy Caucasians. There were 143 aged 18-67 years (60 males and 83 females) and 100 aged 6-12 years (58 males and 42 females). We also compared this association with a known MspI polymorphic site, a G to A transition at -75 bp of the apo AI gene. The rare allele (-) frequency for the polymorphism at +83 bp was 4.1% and 22.1% for the polymorphism at -75 bp. Subjects heterozygous for the loss of the MspI restriction site at +83 bp (genotype: M2+-, n = 20) had higher HDL-C levels than M2+2 subjects (mean +/- SD: 1.73 +/- 0.31 vs. 1.41 +/- 0.39 mmol/l, P < 0.05 for adults; 1.71 +/- 0.33 vs. 1.34 +/- 0.29 mmol/l, P < 0.01 for children). Adults with the G to A substitution at -75 bp also had higher HDL-C levels (1.56 +/- 0.36 mmol/l for AA, 1.53 +/- 0.38 mmol/l for GA, and 1.36 +/- 0.38 mmol/l for GG, P < 0.05); this difference was not observed in the children. The MspI polymorphisms at both sites were in linkage disequilibrium. Their joint effect on the HDL-C levels was also significant and individuals with rare alleles (-) at both sites had the highest HDL-C levels. In an analysis of variance, the MspI polymorphism at +83 bp, and at -75 bp and gender independently accounted for 6.5%, 1.7%, and 5.9%, respectively, of the variance in circulating HDL-C levels when age was controlled as a covariate. We conclude that loss of the MspI site by the C to T (+83 bp) and/or the G to A (+84 bp) transitions is highly associated with increased HDL-C levels. The association appears to be more significant than that of the G to A transition at -75 bp.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8647374     DOI: 10.1002/(SICI)1098-2272(1996)13:1<1::AID-GEPI1>3.0.CO;2-D

Source DB:  PubMed          Journal:  Genet Epidemiol        ISSN: 0741-0395            Impact factor:   2.135


  15 in total

1.  Apolipoproteins AI/B/E gene polymorphism and their plasma levels in patients with coronary artery disease in a tertiary care-center of Eastern India.

Authors:  Santanu Biswas; Pradip K Ghoshal; Bhubaneswar Halder; Kajal Ganguly; Arup DasBiswas; Nripendranath Mandal
Journal:  Indian Heart J       Date:  2013-10-30

2.  Polymorphisms at the 5'-end of the apolipoprotein AI gene and severity of coronary artery disease.

Authors:  X L Wang; S X Liu; R M McCredie; D E Wilcken
Journal:  J Clin Invest       Date:  1996-07-15       Impact factor: 14.808

3.  Contribution of polymorphisms in the apolipoprotein AI-CIII-AIV cluster to hyperlipidaemia in patients with gout.

Authors:  F Cardona; F J Tinahones; E Collantes; A Escudero; E García-Fuentes; F J Soriguer
Journal:  Ann Rheum Dis       Date:  2004-04-28       Impact factor: 19.103

4.  Apolipoprotein A1 gene polymorphisms as risk factors for hypertension and obesity.

Authors:  Elizabeth Suchi Chen; Diego Robles Mazzotti; Tatiane Katsue Furuya; Maysa Seabra Cendoroglo; Luiz Roberto Ramos; Lara Quirino Araujo; Rommel Rodriguez Burbano; Marília de Arruda Cardoso Smith
Journal:  Clin Exp Med       Date:  2009-05-01       Impact factor: 3.984

5.  Association of apolipoprotein A1-C3 gene cluster polymorphisms with gallstone disease.

Authors:  Manjusha Dixit; Gourdas Choudhuri; Rajan Saxena; Balraj Mittal
Journal:  Can J Gastroenterol       Date:  2007-09       Impact factor: 3.522

6.  Effect of apolipoprotein A1 genetic polymorphisms on lipid profiles and the risk of coronary artery disease.

Authors:  BiHong Liao; KeQi Cheng; ShaoHong Dong; HuaDong Liu; ZhengLei Xu
Journal:  Diagn Pathol       Date:  2015-07-16       Impact factor: 2.644

7.  Re-sequencing of the APOAI promoter region and the genetic association of the -75G > A polymorphism with increased cholesterol and low density lipoprotein levels among a sample of the Kuwaiti population.

Authors:  Suzanne A Al-Bustan; Ahmad E Al-Serri; Babitha G Annice; Majed A Alnaqeeb; Ghada A Ebrahim
Journal:  BMC Med Genet       Date:  2013-09-12       Impact factor: 2.103

8.  ApolipoproteinA1-75 G/A (M1-) polymorphism and lipoprotein(a); anti- vs. pro-Atherogenic properties.

Authors:  Ali I Albahrani; Jannete J Usher; Mohammed Alkindi; Eileen Marks; L Ranganath; Said Al-yahyaee
Journal:  Lipids Health Dis       Date:  2007-08-06       Impact factor: 3.876

9.  Apolipoprotein A1 -75 G/A and +83 C/T polymorphisms and renal cancer risk.

Authors:  ZhiHong Liu; YingMing Xiao; LiangYou Tang; Liang Jiang; YuJie Wang; RuoChen Zhang; Qiang Wei; YiPing Lu
Journal:  Lipids Health Dis       Date:  2015-11-04       Impact factor: 3.876

10.  Single nucleotide polymorphisms of APOA1 gene and their relationship with serum apolipoprotein A-I concentrations in the native population of Assam.

Authors:  Kaustubh Bora; Mauchumi Saikia Pathak; Probodh Borah; Md Iftikar Hussain; Dulmoni Das
Journal:  Meta Gene       Date:  2015-11-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.